



People Promoting Elements of Change

Advanced Medical Isotope Corporation

**6208 W. Okanogan Avenue
Kennewick, WA 99336**

Phone: (509) 736-4000

Investor Information

Ticker Symbol
OTCQB: ADMD

Central Index Key (CIK)
0001449349

CUSIP Number
00765X102

OTC Market Tier
OTCQB

Reporting Status
U.S. Registered & Reporting

State Of Incorporation
Delaware

Recent Share Price
\$.20

Authorized Shares
100,000,000

Outstanding Shares
53,339,729
56% insider owned

Transfer Agent
American Registrar & Transfer
Salt Lake City, UT 84111

Chief Executive Officer
James Kataroff



About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (AMIC) is engaging in the production and distribution of medical isotopes and medical isotope technologies that are changing the practice of medicine and ushering in a new era of improved patient care.

Currently, more than 15 million nuclear medicine procedures are performed each year in the U.S. Approximately one-third of all patients admitted to U.S. hospitals undergo at least one medical procedure that employs the use of medical isotopes.

AMIC employs innovative production methods to offer a wide range of reliable, domestically produced medical isotopes as well as in vivo delivery systems to aid medical practitioners and medical researchers in the timely diagnosis and effective treatment of diseases such as cancer, heart disease, neurological disorders, and many other medical conditions.

AMIC's objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential medical isotopes that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients.



Recent Advanced Medical Isotope Corporation News

KENNEWICK, Washington
June 3, 2010
(GLOBE NEWSWIRE)

AMIC Signs Exclusive Global license for "Sub-Critical System" to Produce Mo99



Disclaimer: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this summary, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.